Ascentage Pharma is committed to the development of medicines that address unmet therapeutic needs of patients worldwide.

Ascentage Pharma, a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Tanner Pharma Group (“Tanner Pharma”), a global pharmaceutical services provider of specialty access solutions, have jointly launched an innovative Named Patient Program (NPP) for olverembatinib.

Developed by Ascentage Pharma, olverembatinib is a novel third generation BCR-ABL inhibitor that can effectively target a spectrum of BCR-ABL mutants, including the T315I mutation. Olverembatinib is approved in China for the treatment of adult patients with tyrosine kinase inhibitor (TKI)-resistant chronic phase chronic myeloid leukemia (CP-CML) or accelerated-phase CML (AP-CML) harboring the T315I mutation as confirmed by a validated diagnostic test1. In addition to its approval in TKI resistant CP-CML and AP-CML patients, it has also been included in the CSCO Guidelines in China for the treatment of patients with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Published data on this investigational drug, from an ongoing clinical trial suggests potential of olverembatinib in the management of gastrointestinal stromal tumors (GIST)2.

Named Patient Programs are a mechanism through which physicians can legally prescribe investigational or approved drugs for patients in need prior to their commercial availability. In cases where a patient has exhausted all available treatment options, and enrolment in a clinical trial is not possible, regulators may authorize the use of a medicine that is not commercially available in the patient’s country under the treatment guidance of the patient’s physician. The medicine may be approved and commercially available in one country, but not yet in the patient’s country. Such use of an unapproved medicine is often called “named patient supply”.

To enable access to olverembatinib via named patient supply and manage requests from healthcare providers, Ascentage Pharma has appointed Tanner Pharma as its exclusive partner to support in providing access to treatment in countries where the drug is not commercially available.

For information about accessing olverembatinib via the named patient program, please contact Tanner Pharma Group at:


Phone: +1 704 552 8408 (USA)


  1. Qian J, Zongru L, Yazhen Q, et. al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol 2022 Aug 18;15(1):113.
  2. Qiu H, Zhou Z, Zhou Y, et al. Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). J Clin Oncol 40, 2022 (suppl 16; abstract 11513).